About Me.

Dedication To Developing

Pharmaceutical Formulations

APIs

Surgical, Veterinary, Herbal

Nutraceutical Products

Dr. Deepak Shenoy

Dr. Deepak Shenoy is the founder & Managing Director of one of India’s fastest growing pharmaceutical companies, Ms. Medec Dragon Pvt Limited, an internationally acclaimed research based pharmaceutical company engaged in the manufacturing & marketing of Pharmaceutical API’s. 

Deepak successfully completed Master’s in Business Management in International Business from the University of Chennai. Dr. Deepak Shenoy, Managing Director of Medec Dragon Pvt Limited has been accorded with an Honorary Doctorate in pharmaceutical science and global health by Dr. APJ Abdul Kalam University and Research Centre. The honour has been conferred for his dedication and contributions to the advancement of pharmacy worldwide

Founded in the Year 2010, Medec Dragon Pvt Ltd is a Pharmaceutical company that has achieved Export House status through unwavering dedication, consistent efforts, and endless innovation. Dr. Deepak believes that “Work hard in silence, let the quality of your work make the noise.” Dr. Deepak Shenoy is responsible for worldwide strategy and commercial growth at Medec Dragon Pvt Limited.

Deepak has over the years, created & enabled multi-stake holder ecosystem businesses &  is a proven Business Leader and demonstrated skills in Business Conceptualization and Execution, Investor Engagement, Business Strategy, Organization Building, Partner Engagement and Nurturing, Customer Acquisition, Negotiation, Operations Management, Customer Relationship Management, Technology and Team Management. A global business leader, traveled to over 30+ countries especially in emerging markets and created strategic business associations. Deepak is an accomplished business leader that consistently delivers profitable growth in global technology businesses. Delivers results while driving business transformation. Proven ability to lead global teams, and to simplify and optimize complex businesses. Consistently builds high performing and engaged teams that deliver results.

Deepak has a proven track record in developing and executing innovative growth strategies, leading business launches and transformation initiatives; as well as, building lean and agile marketing, sales, product, and service delivery organizations. Deepak has developed Medec’s vision, growth strategies, manufacturing excellence and services capabilities that significantly strengthened go to market positioning, opened new markets, and delivered sustainable growth performance. Holistic thinker, systematic business analyzer, affable people manager, transformational leader, good communicator, effective trainer, passionate teacher and motivational speaker. Experienced in successful P&L management & Growth of “Best in Class” companies, through international business expansions, operational improvements, business excellence initiatives and commercial acumen. Truly committed in building & nurturing high performing teams. Experienced in strategic planning, strategic CRM, new product development, change management, succession planning and business / system integrations. 

Social Interventions

Dr. Deepak Shenoy is a Chairman & Vice President of SLVT TEMPLE GSB SABHA Navi Mumbai and is also a TRUSTEE of VYSTHAPAK COMMITTEE KASHIMATH KALPI.

Affiliations 

The Royal Asiatic Society  UK

The European Institute of Directors  Latvia

Personal Information

• Name
  Dr. Deepak Shenoy
• Address
  Lodha Supremus, 1004, 10th Floor, Saki Vihar Rd, Powai, Mumbai, Maharashtra 400072, India
• Email
  [email protected]

Medec dragon Pvt Ltd.

Medec dragon Exports to over 75 countries globally

• Medec Dragon Pvt Limited has been growing exponentially because of the forward-looking approach of the company with the risk-taking abilities in the current tough situations at a time when the Pharma industry is facing a tough task in pricing, clinical trials hurdles & regulatory approvals. The company Exports to over 75 countries globally.

  The company provides anti-malarial, expectorant, emetic, CNS, anti-retro-viral, ace inhibitor, erectile dysfunction, animal health, anti-cancer, and diabetic APIs, as well as pain management products. It also offers formulations, such as anti-malarial finished dosages, animal health products, anti-TB drug therapy products, expectorants/cold preparations /mucolytics, lozenges, multi-vitamin syrups, analgesics, anti-obesity products, erectile dysfunction and hormone replacement therapy products, and topicals.

Medec Dragon Pvt. Ltd. is a rapidly growing asset-light company that focuses on supplying advanced-stage intermediates and active pharmaceutical ingredients (APIs) across various therapeutic segments, including life-saving drugs such as oncology, cardiovascular, diabetes management, anti-malarials, antibiotics, anti-virals, pain management, among others.

Sustainability at Medec:

Medec has cemented its position as a successful and sustainable company, thanks to its robust IP, highly skilled technical team, and strategic positioning in both the Indian and global markets.

• Medec leverages its access to strong IP by way of various worldwide patents to manufacture products that can compete with even the most aggressive global peers.
• Its technical team is adept at adapting to various manufacturing environments across India, ensuring consistent delivery of high-quality products to all customers.
• Medec has forged strategic partnerships with best-in-class manufacturing partners whose world-class assets are approved by global regulatory agencies, confirming their robust quality assurance systems and sustainable manufacturing practices. These include extensive usage of biocatalytic conversions, flow chemistry, supercritical fluid extraction, and innovative synthetic processes that are highly energy-efficient and safer, among others.
• Medec’s top management boasts extensive experience, enabling them to anticipate global shortages and escalating demand for various APIs and Intermediates. They have secured preferential allotments of key raw materials from global manufacturers at highly competitive rates, resulting in a strong top-line and bottom-line growth trajectory.
• Medec has established lasting relationships with all its customers by offering top-notch logistics and pricing support, along with customer-centric payment terms.
• Medec also enjoys seamless supply of raw materials from its creditors, ensuring sustained supply of quality products and reinforcing the trust among its customers.

Medec remains committed to research and development, constantly identifying and investing in future products and technologies for sustainable growth. Through cutting-edge innovations, Medec strives for better economic and environmental outcomes, while simultaneously building a robust logistics network to deliver quality products to customers across the globe. By leveraging its strong technical expertise, customer-centric approach, and commitment to green chemistry, Medec is poised for continued success in the pharmaceutical industry.

RECOGNITIONS

AWARDS

Dr Deepak Shenoy, Managing Director of Medec Dragon has received many international accolades & recognitions for his towering leadership & visionary global outlook. .

https://youtu.be/g1OP5jJEC-o

Best CEO at European Awards 2021

Honorary Doctorate in the pharmaceutical sector

Global Icon of the year for Emerging Entrepreneur in Healthcare

India’s Most Promising & Innovative Pharma API Company of the Year 2022

 Indian Affairs Most Promising & Innovative Personality of the Year 2021

Inspiring Personality of the Year 2023 Award

Contact me.

LET’S TALK

[email protected]

Lodha Supremus, 1004, 10th Floor, Saki Vihar Rd, Powai, Mumbai, Maharashtra 400072, India

India to become the third-largest economy within the next five years

Nominal GDP or GDP at Current Prices in Q2 2022-23 is estimated at INR 65.31 lakh crore, as against INR 56.20 lakh crore in Q2 2021-22, showing a growth of 16.2% as compared to 19.0% in Q2 2021-22. More details

In the financial year 2021-22, the economic recovery gained further momentum, with GDP growing 20.1% during April to June 2021, as compared to contraction of 24.4% in Q1 2020-21. In the second quarter of 2021-22 (July to September), India’s GDP increased by 8.4% (Rs. 35.73 trillion) over the corresponding period of 2020-21. The growth trend continued in the third quarter (5.4%) as well as in the fourth quarter. As per data released by National Statistical Office (NSO), Ministry of Statistics and Programme Implementation on 31st May 2022, India’s GDP at Constant (2011-12) Prices in Q4 of 2021-22 (January to March 2022) was estimated at Rs 40.78 trillion, showing a growth of 4.1. Overall, India’s GDP in 2021-22  grew by 8.7%  as compared to (-) 6.6% in the previous year. More details

With a resolve to convert the economic setback due to the COVID-19 pandemic into an opportunity to make India self-reliant, and a bigger, stronger and more important part of the global economy, the Prime Minister launched the Atmanirbhar Bharat Abhiyan (self reliant India programme) on 12 May 2020 with the announcement of a stimulus package worth nearly Rs.21 trillion (US$277 billion), equivalent to around 10 per cent of national GDP, designed to open up new avenues of trade and investment in the post-Coronavirus economy. This was followed with further stimuli in October and November 2020, taking the total value of stimulus package to Rs. 29.87 trillion, i.e. about 15% of national GDP. Further, the Government of India has shown an appetite for bold policy reforms relating to agriculture markets, labour laws and redefinition of MSMEs, as well as taking concrete steps for employment generation and to create new opportunities for trade and investment.

The implementation of Atmanirbhar Bharat package and calibrated unlocking of the economy have ensured that economic recovery in India has gained momentum across all sectors.  As a result, India received its highest ever total FDI inflow of US$ 83.57 billion in 2021-22, up from US$ 81.72 billion during the year 2020-21, bettering the previous high of US$ 81.72 billion in 2020-21.

At the Investor’s Roundtable organised by Department for Promotion of Industry and Internal Trade (DPIIT), along with Invest India, on 20th April 2022, it was highlighted that India received the highest ever FDI in the last two years.

As per UNCTAD Global Investment Trends Monitor, 2022, the Foreign Direct Investment (FDI) flows to India in calender year 2021 were 26% lower as compared to 2020, because large M&A deals recorded in 2020 were not repeated. (UNCTAD GITM), January 2022, 2022, the Foreign Direct Investment (FDI) flows to India in calender year 2021 were 26% lower as compared to 2020, because large M&A deals recorded in 2020 were not repeated.

However, the World Investment Report 2022, (UNCTAD, 9 June, 2022) ranks India as the world’s 7^th highest recipient of FDI in 2021 calender year, up one notch as compared to the eighth rank in 2020.

Over the years, India has successfully positioned itself as one of the most attractive destinations for Foreign Direct Investment across the globe. India’s FDI inflows have increased 20-fold since FY03-04, when the inflows were US$ 4.3 billion only.

India was the fourth major host of greenfield FDI projects and eighth major host of cross-border M&A deals between 2004 to 2015, according to a research paper titled ‘Future of Regional Cooperation in Asia and Pacific’ released on the Asian Development Bank website on 25 November 2020.

Since January 2020, the Coronavirus (COVID-19) pandemic has taken a huge toll on the global economy. In India as well, the impact of the national lockdown imposed in March 2020, followed by cautious “un-locking” since June 2020, resulted in 6.6% in the GDP for the year 2020-21.